.Attribute Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients with HER2+ innovative bosom cancer and also energetic or stable brain metastases showed consistent intracranial activity as well as wide spread efficacy of T-DXd.